Immunization had up to 77 percent efficacy in a Phase 2 clinical study of 450 children in Burkina Faso.

Engineered Plasmodium parasites form the basis of two experimental malaria vaccines that showed safety and encouraging immune responses in clinical trials.

The study, conducted in Malawi, Kenya, and Ghana, did not obtain informed consent from each parent whose child participated, but rather considered consent “implied” because of the particular experimental design.

The World Health Organization and its partners will test the public health effect of immunization in parts of Malawi, Ghana, and Kenya.

The parasite that causes malaria has evolved to evade many of the drugs that researchers have developed to fight the tropical disease.

Plasmodium falciparum has shown an ability to evade everything we throw at it, most recently artemisinin-based combination therapies, today’s front-line treatment.

The large-scale experiments aim to test how the technology would fare in the wild, if deployed to knock down populations of the pests.

Researchers used the genome sequence of Artemisia annua to boost the plant’s production of artemisinin.

The parasite changes people’s scent, primarily due to an increase in aldehydes.

Geckos could help control mosquito-borne diseases, but their effectiveness depends on the environment.

In lab populations of genetically engineered mosquitoes, mutations arose that blocked the gene drive’s spread and restored female fertility.

Introducing genetic changes into mosquito populations could be key to effective malaria control.

For years, researchers have looked to genetically modify mosquitoes to prevent the spread of malaria. Now they have a promising strategy.

Rather than providing complete protection, the long-awaited vaccine merely delays infection by a few years, scientists show.

Researchers have identified the male-determining gene in the malaria mosquito, whose expression in females is lethal.

Officials’ increased emphasis on mosquito control could benefit public health efforts beyond the ongoing Zika outbreak. 

Using the precision gene-editing tool, researchers demonstrate an ability to create large populations of malaria parasite–resistant mosquitoes.

In the absence of a blood meal, some malaria-transmitting mosquitoes in East Africa feed on an invasive weed, scientists find.

The European Medicines Agency endorses the first-ever malaria vaccine for use in children 6 weeks to 17 months old.